Why ENDRA Life Sciences Stock Is Down 65%

ENDRA Life Sciences Inc NDRA shares are trading lower by some 65% to $0.07 during Tuesday’s session. The company priced a public offering of 61,538,461 shares of common stock (or pre-funded warrants in lieu of shares) with accompanying Series A and Series B warrants. This offering is a “best-efforts” format, so there’s no guaranteed amount of money raised.

ENDRA intends to use the net proceeds from this offering for general business purposes, which may include funding daily operations and ongoing development of their technology. The offering is expected to close by tomorrow, June 5th.

See Also: Indian Stocks Tumble The Most Since March 2020 With Modi’s Party Set To Lose Majority

Should I Sell My NDRA Stock?

Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.

Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.

Shares of ENDRA Life Sciences have lost 94.95% year to date. This compares to the average annual return of -83.03%, meaning the stock has underperformed its historical averages. Investors can compare a stock's movement to its historical performance to gauge whether this is a normal movement or a potential trading opportunity.

Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. ENDRA Life Sciences stock currently has an RSI of 14.7, indicating oversold conditions.

For analysis tools, charting data and access to exclusive stock news, check out Benzinga PRO. Try it for free.

NDRA has a 52-week high of $2.79 and a 52-week low of $0.069.